Compare iShares International Treasury Bond ETF (IGOV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.31B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 8.7× iShares International Treasury Bond ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and BIO-TECHNE Corp for 63 Days on average.
| IGOV | TECH | |
|---|---|---|
Market Cap | $1.31B | $11.37B |
Volume | 493,216 | 3,153,511 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $72.61 |
52-Week Low | $39.65 | $43.31 |
Typical Hold Time | 92 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV is trading at $39.70, down 0.48% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty around its financial health. Recent market news highlights rising global bond yields, which could impact interest-rate sensitive sectors.
The outlook remains cautious due to the bearish technical setup and absence of fundamental clarity. Investment opportunities depend on forthcoming financial disclosures, while risks include market volatility from rising yields and the stock's technical weakness. Investors require updated earnings reports to assess true valuation.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
